Welcome to our dedicated page for Alx Oncology Holdings news (Ticker: ALXO), a resource for investors and traders seeking the latest updates and insights on Alx Oncology Holdings stock.
ALX Oncology Holdings Inc. (Nasdaq: ALXO) is a clinical-stage biotechnology company whose news flow centers on the development of investigational cancer therapies. The company regularly issues updates on its lead CD47 inhibitor, evorpacept, and its EGFR-targeted antibody-drug conjugate, ALX2004, as these programs advance through clinical and preclinical milestones.
News about ALX Oncology often covers clinical trial progress for evorpacept in HER2-positive gastric and gastroesophageal cancers, HER2-positive metastatic breast cancer and indolent B-cell non-Hodgkin lymphoma. Press releases detail study designs, enrollment status, biomarker findings such as CD47 overexpression as a potential predictive biomarker, and data presented at major oncology and immunotherapy conferences, including meetings of the Society for Immunotherapy of Cancer (SITC), the American Society of Hematology (ASH) and the European Society for Medical Oncology (ESMO).
For ALX2004, company announcements highlight preclinical data, poster presentations at scientific conferences such as the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, and updates from the ongoing Phase 1 first-in-human trial in EGFR-expressing solid tumors. These items typically describe dose-escalation progress, safety observations and the rationale for further clinical evaluation.
ALX Oncology also reports quarterly financial results and corporate updates via press releases and related conference calls, which are referenced in Current Reports on Form 8-K. Additional news may include participation in investor conferences, webcasts, and changes in leadership or board composition. Readers who follow ALXO news can use this page to track clinical milestones, data disclosures and corporate developments over time.
ALX Oncology announced its participation in the Jefferies Global Healthcare Conference. The event will take place on June 5, 2024, at 1:00 PM ET in New York, NY. The company, focused on developing therapies to block the CD47 immune checkpoint pathway, will engage in a fireside chat with analyst Michael Yee and hold one-on-one investor meetings. A live webcast of the chat will be accessible via the Investors section of ALX Oncology's website, with a replay available for 90 days.
ALX Oncology reported positive financial results for the first quarter of 2024 and provided a corporate update. The company achieved significant milestones in its clinical trials, including positive data in various cancer treatments. They also announced key appointments and upcoming milestones for their pipeline. Financially, ALX Oncology reported cash, cash equivalents, and investments of $184.5 million as of March 31, 2024, with additional funding secured through an ATM offering.
ALX Oncology Holdings Inc. announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer. With her extensive experience in oncology product development, she is expected to drive the growth of the company during a promising period. The company is focused on developing therapies that target the CD47 immune checkpoint pathway, with upcoming clinical study readouts for evorpacept. Dr. Dillon's background in commercial strategy and portfolio development positions ALX Oncology for further success in the oncology market.
ALX Oncology announced the initiation of a Phase 2 Investigator-Sponsored Trial of neoadjuvant radiation and evorpacept in combination with pembrolizumab for patients with untreated HPV-mediated oropharyngeal cancer. The trial aims to address the need for novel therapies in this patient population.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.